IP Library Granted Patent US 8,338,429
Granted Patent B2
US 8,338,429 · App. 12/615,968 · Granted Dec 25, 2012

2-acylaminothiazole derivative or salt thereof

Assignee: Astellas Pharma, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,338,429
App. No.
12/615,968
Granted
Dec 25, 2012
Kind
B2
Abstract

A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia.

Claims (13)

1. A method for the treatment of idiopathic thrombocytopenia purpura in a subject in need thereof, the method comprising:

administering to a subject in need thereof therapeutically effective amount of a compound selected from the group consisting of:

and pharmaceutically acceptable salts thereof,

wherein idiopathic thrombocytopenia purpura in the subject is treated.

2. The method according to claim 1 , wherein the compound is:

3. The method according to claim 1 or 2 , wherein the method comprises: administering the compound in a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.

4. The method according to claim 3 , wherein the pharmaceutical composition is formulated for oral administration.

5. The method according to claim 4 , wherein the effective amount of the compound is a daily dosage of between about 0.01 and about 1 mg/kg.

6. The method according to claim 5 , wherein the method comprises:

administering the effective amount of the compound in the form of one or more tablets once daily.

7. The method according to claim 3 , wherein the method comprises:

administering the therapeutically effective amount of the compound to the subject having a depressed platelet level, wherein the platelet level in the subject is increased or recovered.

8. The method according to claim 1 or 2 , wherein the method comprises: administering the therapeutically effective amount of the compound to the subject such that administration results in cell proliferation and production of mature megakaryocytes and platelets.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2011
From: SUGASAWA, KEIZO; WATANUKI, SUSUMU; KOGA, YUJI; NAGATA, HIROSHI; OBITSU, KAZUYOSHI; WAKAYAMA, RYUTARO; HIRAYAMA, FUKUSHI; SUZUKI, KEN-ICHI
To: YAMANOUCHI PHARMACEUTICALS CO., LTD
Reel/Frame 026057/0486 →
CHANGE OF NAME Recorded Mar 31, 2011
From: YAMANOUCHI PHARMACEUTICALS CO., LTD
To: ASTELLAS PHARMA, INC.
Reel/Frame 026067/0087 →
Priority Claims (2)
JP 2002-10413 · Jan 18, 2002 · national
JP 2002-10447 · Jan 18, 2002 · national
Continuity (2)
Continuation 10500964
Related Publication 20100222361A1 · Sep 2, 2010